drugset / Trial / NCT01515657

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657 ↗

Phase 3 Completed 40 enrolled PLx Pharma
RandomizedCrossoverSingle-blindPrevention

Summary

This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes.

Timeline

Start
2012-01
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 325 mg —